Surgical Incision Closure Method to Prevent Niche Formation After Cesarean Section- Randomized Controlled Trial
Launched by HADASSAH MEDICAL ORGANIZATION · Feb 21, 2021
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to close the incision made during a cesarean section (C-section) to see if it can help prevent a complication known as a "niche." A niche is a defect that can form at the site of the C-section, which may lead to issues like irregular bleeding, pelvic pain, and discomfort during sex. The researchers want to find out if their unique method of closing the incision can reduce the chances of developing a niche after the surgery.
To participate in this study, women must be having their first C-section and agree to take part in the research. Women who are having a repeat C-section or need an emergency surgery cannot join. If you decide to participate, you will be part of a group that will be monitored to see how this new closure technique works compared to standard methods. This study could help improve outcomes for future mothers undergoing C-sections by potentially reducing complications related to the surgical site.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women at first cesarean delivery
- • Women who consent to the study
- Exclusion Criteria:
- • Women who are having a repeat caesarean section
- • Refusal to participate in the study
- • Urgent or emergent cesarean delivery
About Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a leading healthcare institution based in Jerusalem, Israel, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, HMO leverages its state-of-the-art facilities and multidisciplinary expertise to conduct innovative research across various therapeutic areas. The organization is dedicated to fostering collaboration between clinical researchers, healthcare professionals, and academic institutions, ensuring the highest standards of ethical practice and scientific rigor. HMO's mission is to translate groundbreaking research into effective treatments, ultimately enhancing health outcomes for diverse populations both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Hila Hochler, MD
Principal Investigator
Hadassah Medical Organization
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials